Heska Corporation's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2023 to a ratio of 8.47, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the first quarter 2023. Average receivable collection period, for the Heska in Mar 31 2023 quarter, has decreased to 43 days, compared to 44 days, in the Dec 31 2022 quarter.

If we take a look into Healthcare sector 173 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1666, from overall ranking in the fourth quarter 2022 at 2390.

What is Receivable Turnover Ratio?
What is Heska Corporation Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

HSKA Receivables Turnover Ratio	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter
Y / Y Receivable Change	-15.13 %	-8.85 %	-8.43 %	-11.09 %	-8.69 %
Y / Y Revenue Change	-3.73 %	-2.54 %	2.08 %	-0.39 %	7.1 %
Receivable Turnover Ratio (TTM)	8.47	8.21	8.07	7.86	7.64
HSKA's Total Ranking	# 1666	# 2390	# 1565	# 1175	# 1557
Accounts Receivable average collection period days	43	44	45	46	48
Seq. Receivable Change	-10.57 %	7.77 %	-4.5 %	-7.79 %	-3.95 %
Seq. Revenue Change	-5.96 %	7.88 %	-4.92 %	-0.19 %	-4.8 %

Receivable Turnover Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 4
Healthcare Sector	# 174
Overall Market	# 1666

Receivable Turnover Ratio Statistics
High	Average	Low
9.28	7.87	6.83
(Mar 31 2018)		(Sep 30 2014)

HSKA Company Profile • Back to HSKA Efficiency Comparisons • Compare HSKA Receivables Turnover Ratio to its Competitors

Financial Statements
Heska's Accounts Receivable	$ 28 Millions	Visit HSKA's Balance sheet
Heska's Sales TTM	$ 255 Millions	Visit HSKA's Income Statement
Sources of HSKA's Revenues		Visit HSKA's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
HSKA's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
HSKA's Growth Rates	HSKA's Roa	HSKA's Inventory Turnover Ratio	HSKA's Dividend Comparisons
HSKA's Profitability Ratios	HSKA's Roi	HSKA's Asset Turnover Ratio	HSKA's Dividend Growth
HSKA's Valuation Ratios	HSKA's Roe	HSKA's Financial Strength Ratios	HSKA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2023, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2023	Receivable at quarter ending Mar 31 2023
Electrocore Inc	24.40	$ 9.473 Millions	$ 0.388 Millions
Kiniksa Pharmaceuticals International Plc	24.21	$ 236.336 Millions	$ 9.763 Millions
Valion Bio Inc	22.81	$ 1.893 Millions	$ 0.083 Millions
Voyager Therapeutics Inc	21.80	$ 190.729 Millions	$ 8.750 Millions
Lftd Partners Inc	21.25	$ 51.789 Millions	$ 2.437 Millions
C4 Therapeutics Inc	20.93	$ 27.201 Millions	$ 1.300 Millions
Cv Sciences Inc	20.73	$ 15.906 Millions	$ 0.767 Millions
Arvinas Inc	20.25	$ 139.700 Millions	$ 6.900 Millions
Mymetics Corporation	20.08	$ 1.462 Millions	$ 0.073 Millions
Ainos Inc	19.53	$ 3.482 Millions	$ 0.178 Millions
Dr Reddy s Laboratories Limited	19.24	$ 2,992.000 Millions	$ 155.500 Millions
U S Physical Therapy Inc	18.72	$ 339.479 Millions	$ 18.137 Millions
Theralink Technologies Inc	17.74	$ 0.695 Millions	$ 0.039 Millions
Arbutus Biopharma Corp	16.93	$ 33.125 Millions	$ 1.957 Millions
Innovage Holding Corp	16.89	$ 684.074 Millions	$ 40.506 Millions
Qhslab Inc	16.88	$ 1.241 Millions	$ 0.074 Millions
Thorne Healthtech Inc	16.72	$ 239.301 Millions	$ 14.315 Millions
Akili Inc	16.67	$ 0.500 Millions	$ 0.030 Millions
Tango Therapeutics Inc	16.58	$ 24.868 Millions	$ 1.500 Millions
Emmaus Life Sciences Inc	16.52	$ 21.909 Millions	$ 1.326 Millions
Nutriband Inc	16.47	$ 2.079 Millions	$ 0.126 Millions
Petvivo Holdings Inc	16.44	$ 0.917 Millions	$ 0.056 Millions
Catalyst Pharmaceuticals Inc	16.35	$ 256.480 Millions	$ 15.691 Millions
Zymeworks Inc	16.04	$ 446.144 Millions	$ 27.810 Millions
Clearside Biomedical Inc	16.00	$ 0.984 Millions	$ 0.062 Millions
Chemed Corporation	15.70	$ 2,164.571 Millions	$ 137.860 Millions
Neptune Wellness Solutions Inc	15.37	$ 52.615 Millions	$ 3.423 Millions
Arrowhead Pharmaceuticals Inc	15.05	$ 272.800 Millions	$ 18.123 Millions
Patterson Companies Inc	15.01	$ 6,471.471 Millions	$ 431.274 Millions
Rvl Pharmaceuticals Plc	14.81	$ 37.109 Millions	$ 2.506 Millions

Date modified: 2026-08-29T17:28:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.